Literature DB >> 11907658

Mortality associated with late-onset pneumonia in the intensive care unit: results of a multi-center cohort study.

Pierre Moine1, Jean-François Timsit, Arnaud De Lassence, Gilles Troché, Jean-Philippe Fosse, Corrine Alberti, Yves Cohen.   

Abstract

OBJECTIVE: To evaluate the attributable mortality associated with late-onset nosocomial pneumonia (LOP) while taking into account the severity at admission, the evolution of the patients during the first 4 days after admission to the ICU and the appropriateness of initial empiric antibiotic treatment.
DESIGN: Multicenter cohort study with prospective standardization of diagnostic interventions when nosocomial pneumonia develops.
SETTING: Medical and surgical ICUs of four university-affiliated teaching hospitals. PATIENTS: Seven hundred sixty-four consecutive patients requiring ICU hospitalization for at least 4 days. MAIN OUTCOME MEASURES: The clinical and biological data as well as the therapeutic data and the outcome were prospectively recorded from the day of admission to ICU discharge. Simplified Acute Physiologic Score (SAPS II) and Logistic Organ Dysfunction (LOD) score were collected and computed within the first 4 calendar days of ICU admission. Variables associated with the outcome were selected using a stepwise Cox model. The time to acquisition of the first LOP was then introduced in the final model as a time-dependent covariate. The analysis was stratified by ICU center. Finally, as initial antibiotic therapy could have an impact on the increased risk of death induced by LOP, the Cox model was applied again introducing LOP immediately adequately treated and LOP not immediately adequately treated as two different time-dependent covariates.
RESULTS: Late-onset pneumonia developed in 89 patients (12%). A McCabe score of more than 1, SAPS II score and increases in SAPS between days 1 and 2, days 2 and 3, and days 3 and 4 were significantly associated with an increased risk of death. When the time to acquisition of the first episode of LOP was introduced into the Cox model, the LOP occurrence was associated with increased mortality, even adjusted over the selected prognostic parameters and after stratification by center (hazard ratio (HR)=1.53, 95% CI 1.02-2.3, p=0.04). When LOP immediately adequately treated and LOP not immediately adequately treated were separately introduced into the Cox model, inappropriately treated LOP remained significantly associated with an increased risk of mortality (HR=1.69, 95% CI 1.08-2.65, p=0.022), whereas appropriately treated LOP did not (HR=1.44, 95% CI 0.75-2.76, p=0.27).
CONCLUSION: These data suggest that, in addition to severity scores, the underlying medical conditions and the evolution of severity within the first 4 days in ICU, late-onset pneumonia independently contribute to ICU patient mortality when empirical antibiotic treatment is not immediately appropriate.

Entities:  

Mesh:

Year:  2002        PMID: 11907658     DOI: 10.1007/s00134-001-1172-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  20 in total

1.  Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models.

Authors:  Molière Nguile-Makao; Jean-Ralph Zahar; Adrien Français; Alexis Tabah; Maité Garrouste-Orgeas; Bernard Allaouchiche; Dany Goldgran-Toledano; Elie Azoulay; Christophe Adrie; Samir Jamali; Christophe Clec'h; Bertrand Souweine; Jean-Francois Timsit
Journal:  Intensive Care Med       Date:  2010-03-16       Impact factor: 17.440

2.  The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Authors:  Derek C Angus; Pierre-Francois Laterre; Jeff Helterbrand; E Wesley Ely; Daniel E Ball; Rekha Garg; Lisa A Weissfeld; Gordon R Bernard
Journal:  Crit Care Med       Date:  2004-11       Impact factor: 7.598

3.  Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries.

Authors:  Xin Zhang; Rui Wang; Xiuzhen Di; Bin Liu; Youning Liu
Journal:  J Thorac Dis       Date:  2014-02       Impact factor: 2.895

4.  Impact of selective digestive decontamination on respiratory tract Candida among patients with suspected ventilator-associated pneumonia. A meta-analysis.

Authors:  J C Hurley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-26       Impact factor: 3.267

5.  Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study.

Authors:  Stijn Blot; Koenraad Vandewoude; Francis Colardyn
Journal:  Intensive Care Med       Date:  2003-02-08       Impact factor: 17.440

6.  Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia.

Authors:  Olivier Leroy; Agnès Meybeck; Thibaud d'Escrivan; Patrick Devos; Eric Kipnis; Hugues Georges
Journal:  Intensive Care Med       Date:  2003-09-12       Impact factor: 17.440

7.  Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset.

Authors:  J Vallés; A Pobo; O García-Esquirol; D Mariscal; J Real; R Fernández
Journal:  Intensive Care Med       Date:  2007-06-09       Impact factor: 17.440

8.  Early- and late-onset pneumonia: is this still a useful classification?

Authors:  Petra Gastmeier; Dorit Sohr; Christine Geffers; Henning Rüden; Ralf-Peter Vonberg; Tobias Welte
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

9.  Investigating hospital heterogeneity with a multi-state frailty model: application to nosocomial pneumonia disease in intensive care units.

Authors:  Benoit Liquet; Jean-François Timsit; Virginie Rondeau
Journal:  BMC Med Res Methodol       Date:  2012-06-15       Impact factor: 4.615

Review 10.  Paradoxical ventilator associated pneumonia incidences among selective digestive decontamination studies versus other studies of mechanically ventilated patients: benchmarking the evidence base.

Authors:  James C Hurley
Journal:  Crit Care       Date:  2011-01-07       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.